Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET. A live webcast of the event will be available on

Related Keywords

University Of Pennsylvania ,Pennsylvania ,United States ,Philadelphia ,Stuart Henderson ,Mike Beyer ,William Chou ,Passage Bio Inc ,Sam Brown Inc ,Nasdaq ,Healthcare Communications ,University Of Pennsylvania Gene Therapy Program ,Annual Inflammation ,Immunology Conference ,Passage Bio ,Gene Therapy Program ,Bio Investors ,Bio Media ,Nc ,Chief Executive Officer ,Cns Diseases ,Clinical Programs ,Masg ,Clinical Stage ,Investors Media ,Central Nervous System ,